Global Polycystic Ovary Syndrome Treatment Market Size, Share, and COVID-19 Impact Analysis, By Drugs Class (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-Obesity), By Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030

Industry: Healthcare

RELEASE DATE Apr 2023
REPORT ID SI1691
PAGES 210
REPORT FORMAT PathSoft

Global Polycystic Ovary Syndrome Treatment Market Insights Forecasts to 2030

  • The Global Polycystic Ovary Syndrome Treatment Market Size was valued at USD 3.2 billion in 2021.
  • The market is growing at a CAGR of 4.8% from 2022 to 2030.
  • The Worldwide Polycystic Ovary Syndrome Treatment Market size is expected to reach USD 4.9 billion by 2030.
  • Europe is expected to grow the fastest during the forecast period.

 

Polycystic Ovary Syndrome Treatment Market

Get more details on this report -

Request Free Sample PDF

The Global Polycystic Ovary Syndrome Treatment Market Size is expected to reach USD 4.9 billion by 2030, at a CAGR of 4.8% during the forecast period 2022 to 2030. The industry is also anticipated to rise as a result of research and development into polycystic ovary syndrome.

 

 Market Overview

A hormonal condition known as PCOS, or polycystic ovarian syndrome, occurs frequently in women of childbearing age. PCOS may occur in irregular or extended menstrual cycles or high amounts of male hormones. There is currently no cure for PCOS, however, several drugs are used to control the menstrual cycle and manage the symptoms. A common hormonal endocrine condition that affects women who are of reproductive age is PCOS. (15 to 49 years). The most frequent reason for female infertility in May 2022, according to the Centers for Disease Control & Prevention (CDC), is PCOS. There is not presently a specific medication on the market for this ailment. As a result, the main goal of the treatment plan is to reduce the disorder's symptoms. Due to the vast spectrum of symptoms associated with this illness, a variety of medication classes and pharmacological combinations are employed in its therapy. Therefore, companies are working to create a particular drug or treatment to address the disease's underlying causes. One of the innovators working on the creation of such a medication is AstraZeneca.

 

Report Coverage

This research report categorizes the global polycystic ovary syndrome treatment market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global polycystic ovary syndrome treatment. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global polycystic ovary syndrome treatment. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.

 

Global Polycystic Ovary Syndrome Treatment Market Report Coverage

Report CoverageDetails
Base Year:2021
Market Size in 2021:USD 3.2 Billion
Forecast Period:2021 - 2030
Forecast Period CAGR 2021 - 2030 :4.8%
2030 Value Projection:USD 4.9 Billion
Historical Data for:2017 - 2020
No. of Pages:210
Tables, Charts & Figures:124
Segments covered:By Drugs Class, By Distribution Channel, By Region
Companies covered::Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddys Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Evotec SE, Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, Sun Pharmaceutical Industries Ltd., Bayer AG

Get more details on this report -

Request Free Sample PDF
 

Driving Factors

The growth of the polycystic ovarian syndrome treatment market is driven by an increase in PCOS prevalence, an increase in patient population awareness, and an increase in the adoption of combination therapy. Additionally, the market growth is influenced by the ease of access to PCOS therapies, the increase in demand for PCOS drugs, and technological developments for PCOS investigation. The main element fueling this market's growth is the sharp increase in polycystic ovarian syndrome (PCOS) cases around the globe. Additional factors, such as the rising prevalence of diabetes and obesity in women, the rise in hormonal conditions in women, socioeconomic issues, changes in sedentary behavior, and greater consumption of unhealthful foods are also expected to accelerate the market's total expansion.

 

Restraining Factors

The drugs used to treat polycystic ovarian syndrome have a number of side effects. Drug-related side effects include enhanced insulin resistance, influenced glucose tolerance, weight gain, and thromboembolic events are predicted to hinder market expansion. Additionally, it is anticipated that the unclear etiology and pathophysiology of PCOS, as well as the absence of recognized treatments, may constrain market expansion. Also, the market growth is anticipated to be constrained by the lack of a specific treatment for PCOS disease.

 

Market Segmentation

In 2021, the insulin-sensitizing agent is dominating the market with the largest market share over the forecast period.

Based on the drug class, the global polycystic ovary syndrome treatment market is divided into various segments such as, oral contraceptives, antiandrogen, insulin-sensitizing agents, antidepressants, and anti-obesity. Among these, the insulin-sensitizing agent segment is the major revenue-contributing segment due to the greater use of insulin-sensitizing drugs as the initial PCOS therapy strategy. Additionally, many products are sold widely, including Glucophage XR (Metformin) and other products that contain Troglitazone, Rosiglitazone, and Pioglitazone. Due to their capacity to lower insulin levels, inhibit ovarian androgen synthesis, and balance hormone levels, insulin-sensitizing drugs are essential in therapies.

 

In 2021, the hospital pharmacies segment is dominating the market over the forecast period.

Based on the distribution channel, the global polycystic ovary syndrome treatment market is segmented into hospital pharmacies, drug store & retail pharmacies, and online providers. Out of which the hospital pharmacies segment is expected to dominate over the forecast period due to the demand for polycystic ovarian syndrome medications, such as oral contraceptives, having increased. Moreover, the high prevalence of treatment options and medications for the pricey components of PCOS care, such as treatment for conditions like long-term metabolic health conditions (type-2 diabetes) or reproductive health issues (infertility, abnormal uterine bleeding, menstrual dysfunction, and hirsutism), can also be attributed to this segment's high market share.

 

Regional Segment Analysis of the Polycystic Ovary Syndrome Treatment Market

  • North America (U.S., Canada, Mexico) 
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Rest of APAC)
  • South America (Brazil and the Rest of South America) 
  • The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is dominating the market with the largest market share of 43.1% over the forecast period

 

Polycystic Ovary Syndrome Treatment Market

Get more details on this report -

Request Free Sample PDF

North America accounts for the largest market share during the forecast period due to one of the major factors driving the growth of the market in North America is the rise in PCOS cases as a result of rising rates of obesity and overweight. In addition, more people are becoming aware of the advantages of routine checkups, which is increasing the number of new cases that are diagnosed yearly in this region. Furthermore, it is projected that the U.S.'s ability to attract large market participants like Merck, Abbott, and BMS will have a substantial impact on the nation's ability to generate revenue.

 

Asia-Pacific is anticipated to experience considerable growth over the forecast period, owing to government initiatives to increase awareness of the signs and symptoms of PCOS. Also, the diagnosis of this syndrome among women in the region, and the available treatments.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the polycystic ovary syndrome treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

  • Sanofi S.A.
  • Amneal Pharmaceuticals, Inc.
  • Laurus Labs Limited
  • Zydus Pharmaceuticals, Inc.
  • Prasco Laboratories
  • Dr. Reddy's Laboratories
  • Cadila Pharmaceuticals
  • Novartis International AG
  • Concordia Pharmaceuticals Inc.
  • Evotec SE
  • Covis Pharmaceuticals, Inc.
  • Cardinal Health
  • Aphena Pharma Solutions Tennessee, Inc.
  • Mylan N.V.
  • McKesson Corporation
  • Teva Pharmaceutical Industries Ltd
  • Lupin Pharmaceutical
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG

 

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)

 

Recent Developments

  • In June 2022, Bayer announced the launch of its brand-new Research and Innovation Center at Kendall Square in the United States, increasing the company's presence in one of the most cutting-edge centers for pharmaceutical research and development.
  • In January 2022, in its five-year, multi-target relationship with Evotec, the ovarian biology-focused biotechnology company Celmatix Inc. reported the achievement of a third milestone. The achievement of the milestone of moving a PCOS medication development built around a brand-new therapeutic target identified by Celmatix into hit identification was brought about by Evotec and Bayer AG.
  • In January 2020, a biotechnology company named Evotec and a pharmaceutical and biotechnology company named Bayer AG announced an expansion of their collaboration to explore medication candidates for polycystic ovarian syndrome (PCOS).

                                                                                                                    

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the Global Polycystic Ovary Syndrome Treatment Market based on the below-mentioned segments:

 

Global Polycystic Ovary Syndrome Treatment, By Drug Class

  • Oral Contraceptives
  • Antiandrogen
  • Insulin-Sensitizing Agents
  • Antidepressants
  • Anti-Obesity

 

Global Polycystic Ovary Syndrome Treatment, By Distribution Channel

  • Hospital Pharmacy
  • Drug Store & Retail Pharmacy
  • Online Providers)

 

 Polycystic Ovary Syndrome Treatment, By Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Uk
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies